医学
肺癌
癌症
无容量
不利影响
肿瘤科
免疫疗法
内科学
作者
Adam J. Schoenfeld,Sylvia M. Lee,Bernard Doger,Scott Gettinger,Simon Haefliger,Ammar Sukari,Sophie Papa,Juan Francisco Rodríguez Moreno,Friedrich Graf Finckenstein,Rana Fiaz,Melissa Catlett,G. Chen,Rongsu Qi,Emma L. Masteller,Viktoria Gontcharova,Kaitlyn He
出处
期刊:Cancer Discovery
[American Association for Cancer Research]
日期:2024-04-02
标识
DOI:10.1158/2159-8290.cd-23-1334
摘要
In this phase 2 multicenter study, we evaluated the efficacy and safety of lifileucel (LN-145), an autologous tumor-infiltrating lymphocyte cell therapy, in patients with metastatic non-small cell lung cancer (mNSCLC) who had received prior immunotherapy and progressed on their most recent therapy. The median number of prior systemic therapies was 2 (range, 1-6). Lifileucel was successfully manufactured using tumor tissue from different anatomic sites, predominantly lung. The objective response rate was 21.4% (6/28). Responses occurred in tumors with profiles typically resistant to immunotherapy, such as PD-L1-negative, low tumor mutational burden, and STK11 mutation. Two responses were ongoing at the time of data cutoff, including one complete metabolic response in a PD-L1-negative tumor. Adverse events were generally as expected and manageable. Two patients died of treatment-emergent adverse events: cardiac failure and multiple organ failure. Lifileucel is a potential treatment option for patients with mNSCLC refractory to prior therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI